The DOI matches its Crossref record; 195 of the 196 references it cites were found in a registry or an index; 105 of the 183 sources its claims cite were checked for support.
Targeting macrophages in liver fibrosis
Open accessAbstract
Fibrosis results from excessive deposition of extracellular matrix (ECM) components following tissue injury. While initially protective, chronic injury drives pathological ECM accumulation, tissue remodeling, and organ dysfunction. In the liver, fibrosis represents a common endpoint of chronic diseases, including metabolic dysfunction–associated steatotic liver disease (MASLD). Macrophages are central players of the fibrotic hepatic niche, modulating inflammatory signals, immune regulation, and tissue repair. Recent advances demonstrate that hepatic macrophages form a heterogeneous and highly dynamic compartment, adopting diverse activation states that extend far beyond the classical M1/M2 paradigm. Importantly, liver fibrosis is now recognized as a potentially reversible process, with resolution being closely linked to the reprogramming of macrophages towards restorative phenotypes characterized by enhanced efferocytosis, reduced pro-inflammatory signaling, and increased matrix degradation capacity. As a result, efforts to design macrophage-based therapeutic strategies are shifting from non-specific approaches such as inhibition of monocyte recruitment towards approaches that actively promote pro-resolution programs, including targeted in situ reprogramming and more recently cell-based macrophage therapies. In this review, we summarize the hepatic macrophage landscape in the fibrotic liver and discuss current opportunities and challenges in developing macrophage-based anti-fibrotic therapies.
Overview
CoChat Summary
## TL;DR
This is a review of how hepatic macrophage biology can be leveraged for anti-fibrotic therapy in liver fibrosis. It argues that because macrophages are heterogeneous, plastic, and sometimes reparative, the field is moving away from broad monocyte-recruitment blockade toward targeted reprogramming and cell-based approaches.
## Key findings
- Liver fibrosis is a major global problem: the paper states liver pathologies contribute to more than 2 million deaths annually, and MASLD prevalence has been estimated at 30.05% in adults (20+) in one meta-analysis, 14.4% age-adjusted / 16.1% global in a 2023 analysis, with projections of 1.8 billion cases by 2050.
- Hepatic macrophages are central to both fibrogenesis and resolution: in the liver they comprise about 70% of immune cells, and the paper emphasizes that macrophages can drive either fibrogenic or fibrolytic processes depending on context.
- Broad recruitment blockade has mixed clinical results: in murine models, CCR2 deletion reduced monocyte infiltration and fibrosis; cenicriviroc showed collagen deposition reduction preclinically and improvement in phase IIb, but phase III failed to show significant fibrosis improvement without worsening steatohepatitis in the first year.
- The review highlights promising but still early approaches: dexamethasone-loaded nanoparticles reduced HSC activation and collagen deposition in a chronic liver injury mouse model, but failed in rat models with increased collagen deposition; MATCH phase I macrophage infusions were safe and well-tolerated, but phase II did not improve MELD at 90 days, although later follow-up suggested fewer liver-related adverse effects and improved survival.
## Methods
- This is a narrative review, not an original experimental study; it synthesizes animal and human studies on hepatic macrophages and liver fibrosis.
- The paper draws mainly on murine preclinical models (including CCl4, bile duct ligation, and diet-induced MASH models) and incorporates human data where available.
- Its analysis is a conceptual/thematic synthesis of macrophage heterogeneity, liver macrophage niches, and therapeutic strategies: indirect modulation, recruitment blockade, in situ reprogramming, and cell-based therapies.
## Limitations
- The paper explicitly says translation is limited by the field’s reliance on animal, especially mouse, models, with many therapies showing strong preclinical effects that have failed to translate clinically.
- It also states that the understanding of macrophage fate is incomplete, and that comparable datasets from patients with fibrosis resolution are not currently available; this makes human translation difficult.
- Evident from the text: the article is a review, so its conclusions depend on the quality and comparability of the cited studies rather than on new primary data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
57 Valid · 2 Not valid · 24 Not checked · 33 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In the context of MASLD and MASH, a progressive loss of KCs, where the degree of loss is correlated with the severity of the injury, has been reported (36, 37, 104–106, 108).”
§ Targeting macrophages in liver fibrosis > Hepatic macrophages and liver fibrosis In the murine and human liver, macrophages are the most abundant immune cell type, representing around the 70% of all immune cells. This makes the liver one of the organs with the highest proportion of macrophages across the body (97). KCs occupy a unique strategic position within the sinusoidal lumen. In mice, KCs are predominantly found peri-portally, where they are constantly exposed to microbial products and food metabolites arriving from the gut via the portal vein (98). In this niche, KCs function as immune sentinels, maintaining the balance between tolerating harmless antigens that should not provoke an immune reaction and inducing a rapid defense response against pathogenic antigens (60, 61). While KCs are also found peri-portally in humans, recent evidence suggests they are more enriched in peri-central regions (99). Although the functional relevance of this remains to be determined, it has been postulated that this is to aid in the clearance of dying hepatocytes, which may turn over more rapidly in peri-central regions in humans due to higher metabolic activity (99). Across species, KCs are also proposed to play key roles in liver homeostasis, including clearance of senescent cells, cellular debris, and old erythrocytes, as well as endotoxins, immune complexes, and other potentially harmful molecules from the bloodstream (98, 100). In addition, KCs help to regulate iron and lipid metabolism and contribute to immune tolerance in the liver by producing anti-inflammatory mediators (60, 71, 98, 101). In addition to KCs, the liver contains a dynamic pool of macrophages derived from circulating monocytes. During homeostasis, monocyte contribution to KCs is limited, even in humans (102), and is rather restricted to the minor populations of capsule, central vein, and bile-duct macrophages (for more information on these minor populations, we refer to the review of liver macrophages in health and disease (60)). However, during chronic liver injury, large numbers of bone marrow monocytes are recruited to the liver, where they differentiate into MDMs, which can be found throughout the liver, including within the KC niche of the liver sinusoids. As such, MDMs represent a heterogeneous population that can adopt diverse functional states and fates depending on the inflammatory context, niche, and duration of injury (36, 37, 92, 94, 103–106). Macrophage identity is often defined by the expression of specific surface and intracellular markers. Within the human liver, resident KCs are identified as CD68+ macrophages co-expressing VSIG4, TIMD4, CD163, and CD5L, while non-KCs, including MDMs, capsule macrophages and bile-duct macrophages are identified as CD68+ cells lacking these KC markers (60, 62). Recruited MDMs initially express markers such as Ly6C (in mice), CCR2, and CX3CR1, but these markers are often transient, being lost as these cells differentiate from monocyte to macrophage (44, 60, 96, 105). MDMs that occupy the KC niche become what is termed monocyte-derived KCs (MoKCs), expressing all KC markers except TIM4, although as a maker of residency, this can also be acquired over time (25, 104). While specific markers have been considered to accompany activation status, whereby pro-inflammatory macrophages typically express high levels of CD86 and MHC-II, and reparative or anti-inflammatory macrophages often express CD163 and CD206 (107), marker expression regularly overlaps across activation states. As they can be dynamically regulated during injury and repair, the use of these markers to define macrophage functions should therefore be avoided. Indeed, in both the human and murine healthy liver, KCs (identified as VSIG4+TIM4+) express CD163, CD206, MHCII and CD86, demonstrating that these cells do not fit into either the pro-inflammatory or reparative categories based on these markers alone (62). Moreover, it has recently been shown that upon activation, resident murine KCs can lose expression of the canonical KC markers, including TIM4, VSIG4 and CLEC4F (91, 94). Thus, discrimination between hepatic macrophage subsets based on a restricted set of markers is unreliable, and ontogeny and niche context must be taken into account (96). In the context of MASLD and MASH, a progressive loss of KCs, where the degree of loss is correlated with the severity of the injury, has been reported (36, 37, 104–106, 108). In mice, KC loss has been attributed to death via apoptosis (37, 106), although whether this holds true across all models of murine MASLD and in humans remains unclear. This loss of resident KCs is accompanied by the influx of monocytes to the liver, which can engraft and differentiate into MDMs. Those recruited to an intact empty KC niche become MoKCs, which do not express TIM4 initially, but can be acquired over time (104). On the other hand, those monocytes recruited to zones of steatosis and fibrosis appear to take on an alternative profile, which has been given multiple names, including lipid-associated macrophages (LAMs), scar-associated macrophages (SAMs) and NASH-associated macrophages (NAMs) (31, 104, 108, 109). Notably, these cells exhibit a very similar transcriptional profile, with the precise name (LAM, SAM, or NAM) reflecting the different studies in which these cells were identified. For the sake of clarity, here we will refer to all of these populations as LAMs. However, it is clear from this that macrophage nomenclature represents a major challenge in current macrophage research, and effort needs to be invested into the development of a consensus strategy for naming these cells (Box 1). LAMs in both mice and humans, are characterised by the expression of TREM2, CD9, SPP1 (osteopontin), FABP5, and GPNMB (36, 109). Interestingly, this phenotype is not unique to the fibrotic liver, also being identified in other tissues in the context of sterile injury (32, 33, 38, 110–121) as well as in macrophages surrounding the bile duct in the healthy liver (62). Moreover, LAM-associated genes can also be detected in murine and human resident KCs upon sterile injury, e.g., MASH/fibrosis, and these activated KCs have been termed LAM-like KCs (36). Together, these findings argue against the LAMs being a distinct subset of macrophages, but rather support the idea that this may represent a functional state that can be adopted by any macrophage when exposed to specific microenvironmental signals, including lipids, apoptotic cells, and ECM components, irrespective of origin (Figure 3) (34, 97). In this regard, understanding the fate of LAMs in the fibrotic liver, becomes even more poignant. Does this state represent an end-point of differentiation, or do these cells retain plasticity and later convert their phenotype (Figure 3)? A re-examination of monocyte-KC development following resident KC depletion in mice has shown that monocytes entering the liver also temporally upregulate LAM-associated genes (although to a much lesser extent than observed in recruited MDMs in injury, Figure 3), raising the possibility that all macrophages may go through a LAM intermediate stage. Sophisticated fate mapping tools for the LAM-phenotype will be required to address these questions. With the increasing affordability of single-cell transcriptomics, numerous studies have been conducted to investigate macrophage heterogeneity across a range of disease states. This has led to a better understanding of the different macrophage populations present, but has also led to many different names being given to macrophage subsets that appear across disease models, which causes confusion and prevents alignment between studies. A good example of this is the population of macrophages in the fibrotic liver, which have been called LAMs, SAMs, and NAMs in different studies, despite largely sharing a conserved transcriptional profile (31, 104, 108). Part of the reason for this is the pressure for novelty in publications, whereby claiming the presence of a new population of macrophages increases interest. The other main cause of this is the lack of a consensus regarding macrophage nomenclature. Importantly, this is not a question of semantics, as the names we give to cells can have significant consequences. For example, identifying a population of macrophages as pro-fibrotic in one tissue may make them an interesting target for therapeutic intervention. However, if the same population also fulfills a different function and is given a different name, then this overlap may be missed, and the therapy may fail, resulting in a waste of resources. So how should we name macrophage populations? Obviously here we need to come to a consensus as a field and no one group can decide this unanimously, however to start the discussion, we would propose that multiple aspects should be present in the name including the tissue where it is described, (putative) functions, ontogeny and the markers it expresses, which in our opinion, would allow cross context, tissue and species comparisons to be made between populations. Of course, all of this will lead to a long name, which makes it less attractive, thus we would propose to draw parallels with how humans are named in Western cultures. Firstly, we would propose a formal “legal” name for any macrophage, consisting of a title, first name, middle name, and surname. Here the title would detail the tissue in which the macrophage was identified, the first name would highlight 2–3 of the top marker genes for the population, the middle name would cover ontogeny, and the surname would detail (putative) functions and/or a historical name (e.g. for resident macrophage populations such as KCs, microglia, Langerhan’s cells etc). We suggest 2–3 top marker genes to enable a quick comparison between populations that does not rely on 1 marker, as the top gene may differ based on study design. Moreover, we highlight putative functions, as while ideally these would be confirmed functions, they are not always investigated in the initial studies describing the cells for one reason or another, including the lack of specific tools allowing the functions of the ‘new’ macrophages to be defined. To give concrete examples, this would lead to the names: Liver VSIG4+TIM4+ embryonically-derived Kupffer cells for what are now referred to as resident KCs, Liver TREM2+GPNMB+ monocyte-derived repair-associated macrophages for LAMs/SAMs/NAMs, Liver VSIG4+TIM4- monocyte-derived Kupffer cells for moKCs, and Liver TREM2+GPNMB+ embryonically-derived (repair-associated) Kupffer cells for LAM-like KCs. However, as these names are long, we would then propose that after a first formal introduction, these names would be shortened to include only the first name and surname, leading to VSIG4+TIM4+ KCs, TREM2+GPNMB+ repair-associated macrophages (RAMs), VSIG4+TIM4- KCs, and TREM2+GPNMB+ repair-associated KCs (RAKCs). Again, we want to emphasize that this is only a suggestion, designed to further stimulate discussion and an eventual consensus around this important topic. The functional role of the distinct hepatic macrophage populations in the context of fibrosis is also an area of intense investigation, critical for the design of novel macrophage-based therapeutics and here also a number of questions still remain. For example, if the loss of resident KCs could be prevented, would this be beneficial? To date, considerable effort has been focused on the function of the LAMs, being the predominant macrophage population in the fibrotic liver. However, without tools to study these cells specifically, we still have more questions than answers. While the majority of murine studies to date have suggested a role for LAMs/LAM-like KCs in tissue repair, contributing to dead cell and lipid clearance, thus reducing lipotoxic stress, and preventing uncontrolled inflammation (36, 108, 122–126), these cells also produce mediators such as SPP1 and TGF-β that activate HSCs and hence may promote fibrogenesis (31). It remains unclear whether this activation is a beneficial fibrotic response required for tissue repair or whether it instead drives pathological fibrosis. The former option is supported by murine studies suggesting overexpression of Spp1 in macrophages would ameliorate fibrosis and MASLD (127). However, evidence for the latter option also exists as, in mice, reduced fibrosis has been shown to correlate with the loss of LAMs (109). Thus, LAMs may have both protective and pathogenic roles, but exactly why this would be the case and how this would be regulated remains to be investigated. One hypothesis in this regard would be that the function of these macrophages may be dependent on the time spent in the fibrotic tissue. For example, the LAM phenotype may be induced to help clear debris and lipids, activating HSCs to induce tissue fibrosis needed for tissue repair, but with continued exposure to such signals, these cells may become overwhelmed and dysfunctional, leading to impaired clearance while continuing to produce pro-fibrotic mediators, exacerbating disease (Figure 3). Alternatively, different subsets of LAMs may exist with distinct functions. Thus, it is clear that additional studies are needed to address these outstanding questions. However, at this time, our ability to answer these questions is somewhat limited by the availability of tools and technologies. For example, to date, no LAM-specific Cre driver or inducible fate-mapping mouse models exist to selectively trace, deplete, or conduct gain/loss-of-function experiments with LAMs in vivo at defined disease stages. Such tools would allow us to test the temporal hypothesis, where LAMs could be initially protective but later become pathogenic, or the co-existence of distinct LAM subpopulations with opposing functions recruited at different times or from different precursors. Complementary approaches, such as CRISPR-based in vivo screens, could enable the modulation of LAM-associated genes and hence functions without the need for genetic models, however here the temporal element becomes more challenging. Moreover, strategies still need to be devised to specifically target guide mRNAs to LAMs, particularly in the absence of a LAM mouse model where Cas9 expression could be limited to LAMs. This represents a key challenge given the highly phagocytic nature of the different hepatic macrophage populations. Indeed, previous studies in mice using ex vivo isolated macrophage populations have shown that KCs are considerably more phagocytic than LAMs (36). Beyond animal models, human liver organoid co-culture systems combined with CRISPR-based in vitro technologies could shed some light on the roles of LAMs, however here the bottleneck is the generation of bona fide LAMs in vitro. Current evidence suggests a role for efferocytosis in their generation (36), however, a more in-depth understanding of these cells and for example the transcription factors governing their identity will likely be required to engineer these cells effectively in vitro. Thus, taken together, these studies and our current technical limitations highlight the need for further research efforts into these populations before we can really start to think about deploying LAM-targeted therapies.
What the sources say
- Not checked — no full text of the sourcecites [36] De Ponti, 2025, Spatially restricted and ontogenically distinct hepatic macrophages are required for tissue repair, Immunity source
- Not checked — no full text of the sourcecites [37] Seidman, 2020, Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis, Immunity source
- Partly supportedcites [104] Remmerie, 2020, Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the fatty liver, Immunity sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) report gradual loss of resident Kupffer cells in MAFLD, supporting the progressive-loss part of the claim. The passages do not establish that the degree of Kupffer-cell loss correlates with injury severity; the Discussion instead links worsening disease and fibrosis to the appearance of recruited macrophages. (LLM, conf=0.85)
- Partly supportedcites [105] Daemen, 2021, Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH, Cell Rep sourceExperimental — accuracy not yet measured
The Results section (“Macrophage Dynamics with NAFLD Progression”) reports a decline in resident TIM4-positive KCs during high-fat-diet-driven disease progression in mice. The Discussion likewise states that resident KCs are lost as steatosis progresses to NASH. Our copy does not report that the degree of KC loss correlates with injury severity, so that part of the claim is unsupported by this source. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [106] Tran, 2020, Impaired Kupffer cell self-renewal alters the liver response to lipid overload during non-alcoholic steatohepatitis, Immunity source
- Disputedcites [108] Xiong, 2019, Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis, Mol Cell sourceExperimental — accuracy not yet measured
The Results section (page unavailable) reports a marked expansion of Kupffer cells in NASH livers, contrary to the claimed progressive loss. It associates Trem2 and Gpnmb expression—not the degree of KC loss—with liver injury and fibrosis. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Importantly, liver fibrosis is now recognized as a potentially reversible process, with resolution being closely linked to the reprogramming of macrophages towards restorative phenotypes characterized by enhanced efferocytosis, reduced pro-inflammatory signaling, and increased matrix degradation capacity.”
§ Targeting macrophages in liver fibrosis > Abstract Fibrosis results from excessive deposition of extracellular matrix (ECM) components following tissue injury. While initially protective, chronic injury drives pathological ECM accumulation, tissue remodeling, and organ dysfunction. In the liver, fibrosis represents a common endpoint of chronic diseases, including metabolic dysfunction–associated steatotic liver disease (MASLD). Macrophages are central players of the fibrotic hepatic niche, modulating inflammatory signals, immune regulation, and tissue repair. Recent advances demonstrate that hepatic macrophages form a heterogeneous and highly dynamic compartment, adopting diverse activation states that extend far beyond the classical M1/M2 paradigm. Importantly, liver fibrosis is now recognized as a potentially reversible process, with resolution being closely linked to the reprogramming of macrophages towards restorative phenotypes characterized by enhanced efferocytosis, reduced pro-inflammatory signaling, and increased matrix degradation capacity. As a result, efforts to design macrophage-based therapeutic strategies are shifting from non-specific approaches such as inhibition of monocyte recruitment towards approaches that actively promote pro-resolution programs, including targeted in situ reprogramming and more recently cell-based macrophage therapies. In this review, we summarize the hepatic macrophage landscape in the fibrotic liver and discuss current opportunities and challenges in developing macrophage-based anti-fibrotic therapies.
What the sources say
- Supportedcites [87] Pei, 2023, Liver fibrosis resolution: from molecular mechanisms to therapeutic opportunities, Int J Mol Sci source
Section 3, “Regression of Liver Fibrosis” (page unavailable), describes fibrosis as reversible and says that removing the liver-injury stimulus can shift macrophages from a pro-inflammatory to a repair state. This supports the attributed link between fibrosis resolution and macrophage reprogramming. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [88] Henderson, 2007, Liver fibrosis: cellular mechanisms of progression and resolution, Clin Sci source
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Macrophages are central players of the fibrotic hepatic niche, modulating inflammatory signals, immune regulation, and tissue repair.”
§ Targeting macrophages in liver fibrosis > Abstract Fibrosis results from excessive deposition of extracellular matrix (ECM) components following tissue injury. While initially protective, chronic injury drives pathological ECM accumulation, tissue remodeling, and organ dysfunction. In the liver, fibrosis represents a common endpoint of chronic diseases, including metabolic dysfunction–associated steatotic liver disease (MASLD). Macrophages are central players of the fibrotic hepatic niche, modulating inflammatory signals, immune regulation, and tissue repair. Recent advances demonstrate that hepatic macrophages form a heterogeneous and highly dynamic compartment, adopting diverse activation states that extend far beyond the classical M1/M2 paradigm. Importantly, liver fibrosis is now recognized as a potentially reversible process, with resolution being closely linked to the reprogramming of macrophages towards restorative phenotypes characterized by enhanced efferocytosis, reduced pro-inflammatory signaling, and increased matrix degradation capacity. As a result, efforts to design macrophage-based therapeutic strategies are shifting from non-specific approaches such as inhibition of monocyte recruitment towards approaches that actively promote pro-resolution programs, including targeted in situ reprogramming and more recently cell-based macrophage therapies. In this review, we summarize the hepatic macrophage landscape in the fibrotic liver and discuss current opportunities and challenges in developing macrophage-based anti-fibrotic therapies.
What the sources say
- Partly supportedcites [7] Long, 2023, Macrophages and fibrosis: How resident and infiltrating mononuclear phagocytes account for organ injury, regeneration or atrophy, Front Immunol sourceExperimental — accuracy not yet measured
The resolution of tissue fibrosis section describes macrophages degrading fibrotic matrix in liver injury, while the resolution of inflammation section describes their roles in immunoregulation and repair. Those latter roles are discussed across tissues, not specifically within a fibrotic hepatic niche, so the liver-specific scope of the full claim is not established. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, these recent transcriptomic, proteomic, and epigenetic studies have demonstrated that macrophage activation should not be classified as an on/off light switch system (e.g., M1/M2), but rather as a continuous spectrum of activation states (10, 30).”
§ Targeting macrophages in liver fibrosis > Macrophage heterogeneity and plasticity
What the sources say
- Supportedcites [10] Locati, 2019, Diversity, mechanisms, and significance of macrophage plasticity, Annu Rev Pathol: Mech Dis Annu Rev Pathol Mech Dis source
In “Macrophage plasticity: priming, polarized activation, training and tolerance” (page not provided), the paper explicitly describes M1 and M2 as extremes of a continuum of activation states. It also says transcriptional profiling extended the spectrum well beyond the M1/M2 dichotomy. (LLM, conf=0.94)
- Supportedcites [30] Xue, 2014, Transcriptome-based network analysis reveals a spectrum model of human macrophage activation, Immunity source
The Summary (p. 2) says the analysis revealed a spectrum of macrophage activation states extending the M1-versus-M2 model. The Figure 1 discussion (p. 4) explicitly says the data extend that bipolar model to a spectrum, supporting the cited contrast with an on/off classification. (LLM, conf=0.93)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“One of the most promising developments in the field is the growing consensus that liver fibrosis can be a reversible process under certain conditions, particularly if the underlying cause of injury is removed (84–86).”
§ Targeting macrophages in liver fibrosis > Liver fibrosis > Pathology of liver fibrosis
What the sources say
- Supportedcites [84] Pan, 2018, Morphometry confirms fibrosis regression from sustained virologic response to direct-acting antivirals for hepatitis C, Hepatol Commun source
The Results (Liver Biopsy Status Post-SVR; page unavailable) report reduced fibrosis on repeat biopsies in some patients after a sustained response to hepatitis C treatment. The Abstract (page unavailable) also says morphometric analysis confirmed regression after treatment. This supports the qualified claim that liver fibrosis can be reversible when an underlying cause is addressed. (LLM, conf=0.90)
- Supportedcites [85] Lassailly, 2020, Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis, Gastroenterology source
The Secondary Outcomes section reports that fibrosis improved in 70.2% of patients with baseline fibrosis five years after bariatric surgery. The Discussion says fibrosis can disappear and that fibrolysis continues after suppression of the necroinflammatory process, supporting the qualified claim that fibrosis can be reversible when injury is addressed. (LLM, conf=0.90)
- Not checked yetcites [86] Iredale, 1998, Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors, J Clin Invest source
Checked before — its earlier verdict is held back until a new check runs.
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
56 more claims · 21 with their cited sources checked
Create a free account to see all 116 claims and to verify the 12 references still open.
- It may state two separate claims as one. 49
- Probably not a substantial claim. 12
Citations
Cites
Janeway, C. A., & Medzhitov, R. (2002) · Annual Review of Immunology · doi:10.1146/annurev.immunol.20.083001.084359 · Cited by 8,394 · cited 1×
“DAMPs are recognised by pattern recognition receptors (PRRs), including toll-like receptors (TLRs), which are highly expressed on tissue resident immune cells, such as KCs in mice and humans (69).”
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534 · cited 8×
“While the majority of murine studies to date have suggested a role for LAMs/LAM-like KCs in tissue repair, contributing to dead cell and lipid clearance, thus reducing lipotoxic stress, and preventing uncontrolled in fl ammation (36, 108, 122 – 126), these cells also produce mediators such as SPP1 and TGF-b that activa…”
InfluentialA Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
The M1 and M2 paradigm of macrophage activation: Time for reassessment
Martinez, F. O., & Gordon, S. (2014) · F1000Prime Reports · doi:10.12703/p6-13 · Cited by 4,689 · cited 4×
“In contrast, M2 were linked to a wound healing and tissue remodeling phenotype expressing IL-10, arginase-1, CD206, and secreting TGF-b (29).”
InfluentialCellular and molecular mechanisms of fibrosis
Wynn, T. (2008) · The Journal of Pathology · doi:10.1002/path.2277 · Cited by 4,495
Macrophages in Tissue Repair, Regeneration, and Fibrosis
Wynn, T. A., & Vannella, K. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.015 · Cited by 4,481
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383 · cited 1×
“A systematic review and meta-analysis study from 1990 to 2019 estimated global MASLD prevalence in adults aged 20 and over at 30.05% (50).”
Influential
Research works printed but not linked: 5
- Davies, 2013, Tissue-resident macrophages, Nat Immunol, 14, 10.1038/ni.2705 · DOI · Paper page
- Younossi, 2023, The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review, Hepatology, 77, 10.1097/HEP.0000000000000004 · DOI · Paper page
- Satdarshan, 2010, Gross and cellular anatomy of the liver, 2
- Anstee, 2024, Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study, Clin Gastroenterol Hepatol, 22, 124, 10.1016/j.cgh.2023.04.003 · DOI · Paper page
- Harrison, 2020, Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials, J Hepatol, 73, 26, 10.1016/j.jhep.2020.02.027 · DOI · Paper page
Cited by
Zhu, L., & Wu, B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1899587 · Cited by 1
Kong, M., 张利红, Bai, Y., Jia, J., Liu, C., Liu, W., Chen, S., & Zhang, S. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1926987
He, J., Zhang, W., Liu, P.-P., & Pan, T. (2026) · Food and Chemical Toxicology · doi:10.1016/j.fct.2026.116412
Metadata
- Authors
- González del Barrio, L., Ipsen, D. H., Pfister, D. R., Hancz, D., & Scott, C. L.
- Affiliations
- Laboratory of Myeloid Cell Biology in Tissue Damage and Inflammation, VIB Center for Inflammation Research
- Global Research, Novo Nordisk A/S
- Ghent University (BE)
- Corresponding author
- Scott, Charlotte L.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2026-05-22
- Volume
- 17
- Pages
- 1835489-1835489
- ISSN
- 1664-3224 (ISSN-L)
- PMC
- PMC13236518
- OpenAlex
- W7162093433
- Cited by
- 3
- References
- 194
- Citations by year
- 2026: 3
- FWCI
- 3.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Immunology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, cc-by)
- Funders
- Fonds Wetenschappelijk Onderzoek (G0A9Z24N, G075923N)
- Stichting Tegen Kanker
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Keywords
- liver fibrosis, hepatic macrophages, macrophage heterogeneity, macrophage polarization, non-alcoholic fatty liver disease, extracellular matrix deposition, tissue remodeling, macrophage reprogramming, efferocytosis, antifibrotic therapy, monocyte recruitment
- MeSH terms
- Efferocytosis, Animals, Extracellular Matrix, Humans, Liver, Liver Cirrhosis, Macrophage Activation, Macrophages
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting macrophages in liver fibrosis. https://app.cochat.ai/papers/10.3389/fimmu.2026.1835489
- The paper
- González del Barrio, L., Ipsen, D. H., Pfister, D. R., Hancz, D., & Scott, C. L. (2026). Targeting macrophages in liver fibrosis. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2026.1835489
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.